Drug intelligence / Profile preview

peripheral blood mononuclear cells

Development stage: Phase 1
Modality: Cell Therapies
Administration: Intramuscular, Intra-arterial, Intralesional

Overview

Peripheral blood mononuclear cells (PBMCs) are a mixed population of blood cells with round nuclei, primarily consisting of lymphocytes (T cells, B cells, NK cells) and monocytes. They are isolated from peripheral blood through density gradient separation techniques. PBMCs have demonstrated vascular regeneration capabilities through mechanisms such as angiogenesis, macrophage polarization (from M1 to M2 phenotype), and paracrine stimulation. They are being investigated as a cell-based therapy for various conditions, particularly critical limb ischemia in diabetic patients, where they can improve blood flow, promote neovascularization, and enhance wound healing.

Other names: peripheral blood mononuclear cells

Beyond the preview

Go deeper on peripheral blood mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on peripheral blood mononuclear cells.

Explore the full profile